Jubilant Pharmova invests Rs 867.2 crore, allots Rs 800 crore NCDs
Key highlights
- Jubilant Pharmova spent Rs 867.2 crore on capital assets in the half year ended 30 September 2026, versus Rs 739.7 crore a year earlier.
- Jubilant Pharmova’s total consolidated borrowings rose to Rs 3,892.2 crore at 30 September 2026 from Rs 3,219.5 crore at 31 March 2026.
- Jubilant Pharmova allotted Rs 800 crore of unsecured NCDs on 5 November 2026 after board approval on 12 October 2026.
- Jubilant Pharmova generated Rs 380.2 crore of operating cash and used Rs 797.4 crore in investing activities during the first half.
powered by IRIS

Jubilant Pharmova Limited spent Rs 867.2 crore on property, plant, equipment and intangible assets in the half year ended 30 September 2026, exceeding net operating cash generation of Rs 380.2 crore, while total consolidated borrowings rose Rs 672.7 crore from 31 March and Jubilant Pharmova subsequently allotted Rs 800 crore of unsecured NCDs on 5 November 2026.
Know Jubilant Pharmova inside out
Results, valuation, peers and who's buying, in one view.
How much did Jubilant Pharmova invest in the first half?
Jubilant Pharmova spent Rs 867.2 crore on property, plant, equipment and other intangible assets in the half year ended 30 September 2026, compared with Rs 739.7 crore in the half year ended 30 September 2025. The Rs 127.5 crore increase was recorded in the cash-flow statement’s investing section, and the purchase line includes capital work-in-progress and intangible assets under development.
The investment outlay was larger than the Rs 380.2 crore of net cash generated from operating activities in the 2026 half year. After including Rs 57.1 crore of asset-related government grants, Rs 13.4 crore of interest received and other listed items, net cash used in investing activities was Rs 797.4 crore, up from Rs 631.2 crore a year earlier.
Jubilant Pharmova’s balance sheet also showed higher development-stage and construction assets at 30 September 2026. Capital work-in-progress rose Rs 745.1 crore in six months to Rs 3,706.6 crore, while intangible assets under development rose Rs 165.5 crore to Rs 1,244.4 crore; property, plant and equipment increased Rs 40.7 crore to Rs 3,550.3 crore.
How did Jubilant Pharmova’s borrowings and cash position change?
Jubilant Pharmova’s total consolidated borrowings were Rs 3,892.2 crore at 30 September 2026, up Rs 672.7 crore from Rs 3,219.5 crore at 31 March 2026. Non-current borrowings increased Rs 461.5 crore to Rs 3,433.2 crore, and current borrowings increased Rs 211.2 crore to Rs 459 crore over the same period.
During the half year, Jubilant Pharmova received Rs 536.6 crore from long-term borrowings and repaid Rs 56.2 crore of such borrowings. Net short-term borrowings added Rs 156.3 crore, while the company paid Rs 137.4 crore in finance costs, Rs 78.9 crore in dividends and Rs 41.7 crore in lease liabilities, resulting in financing cash inflow of Rs 371.2 crore.
The prior-year comparison differed: financing activities used Rs 184.4 crore in the half year ended 30 September 2025. In that period, Rs 2,058.7 crore of long-term borrowing proceeds were substantially offset by Rs 1,974.5 crore of repayments, whereas the 2026 half-year long-term borrowing proceeds exceeded repayments by Rs 480.4 crore.
Cash and cash equivalents were Rs 1,219.8 crore at 30 September 2026, down Rs 47.3 crore from Rs 1,267.1 crore at 31 March 2026. The reported decrease followed the Rs 797.4 crore investing outflow, partly offset by operating and financing inflows, as well as a Rs 1.3 crore adverse effect from exchange-rate changes.
Got a follow-up? Ask IRIS
What did Jubilant Pharmova’s Rs 800 crore NCD allotment involve?
Jubilant Pharmova allotted unsecured non-convertible debentures, or NCDs, totalling Rs 800 crore to successful bidders on 5 November 2026. The allotment followed the Board of Directors’ 12 October 2026 approval for a private-placement programme of up to Rs 800 crore, and it occurred after the 30 September 2026 balance-sheet date.
The board approval covered up to 80,000 fully paid-up, rupee-denominated, listed, rated, redeemable and transferable NCDs with a face value of Rs 1 lakh each. It permitted secured or unsecured instruments and issuance in one or more tranches, while the NCDs actually allotted on 5 November were unsecured.
The 13 November 2026 results filing does not disclose a coupon rate, maturity date, redemption schedule or stated use of proceeds for the Rs 800 crore allotment. It also does not add the November issuance to the Rs 3,892.2 crore borrowing balance reported as at 30 September 2026, which predates the allotment.
Which business segments and profits changed in the first half?
Jubilant Pharmova reported revenue from operations of Rs 4,599.4 crore for the half year ended 30 September 2026, up Rs 732.3 crore from Rs 3,867.1 crore in the comparable 2025 half. Radiopharma remained the largest reported segment by revenue at Rs 2,031.4 crore, followed by Contract Development and Manufacturing Organisation, or CDMO, Sterile Injectables at Rs 1,079.4 crore.
Segment earnings moved differently from segment revenue. Radiopharma’s result fell to Rs 147.8 crore from Rs 194.1 crore, Allergy Immunotherapy declined to Rs 129.2 crore from Rs 136.2 crore, and CDMO Sterile Injectables fell to Rs 3.1 crore from Rs 114.1 crore despite that segment’s revenue increasing Rs 275.3 crore year on year.
Total segment results declined to Rs 312.9 crore from Rs 490.6 crore. After Rs 112.6 crore of finance costs and Rs 52.2 crore of exceptional items and unallocable expenditure net of unallocable income, profit before tax was Rs 148.1 crore, compared with Rs 344.7 crore in the prior-year half; profit for the period was Rs 87.4 crore against Rs 222.4 crore.
CDMO Sterile Injectables held Rs 6,712 crore of segment assets at 30 September 2026, up from Rs 6,058.3 crore at 31 March 2026. Its segment liabilities also increased to Rs 3,036.1 crore from Rs 2,785.2 crore, while total consolidated assets rose to Rs 16,664.6 crore from Rs 15,522.7 crore in the same six-month period.
Conclusion
The half-year results show that Jubilant Pharmova’s Rs 867.2 crore capital-asset spending exceeded its Rs 380.2 crore operating cash generation, alongside a Rs 672.7 crore increase in reported borrowings by 30 September 2026. The subsequent Rs 800 crore NCD allotment adds another disclosed financing event, but the filing does not state that its proceeds were earmarked for the first-half investment programme.
The next filing can show whether capital work-in-progress of Rs 3,706.6 crore and intangible assets under development of Rs 1,244.4 crore move into completed assets. Investors can also watch for any further disclosure on the Rs 800 crore NCDs, including coupon, maturity and redemption terms, which were unresolved in the 13 November 2026 results announcement.


